Eli Lilly secured federal approval for Emgality, the first migraine treatment approved in the U.S. for decreasing the frequency of episodic cluster headache attacks, the FDA announced June 4. 1.
The healthcare bellwether’s performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters. It delivered a four-quarter earnings surprise of 8.47%, ...
Eli Lilly And Co LLY announced that post-hoc analysis of three Phase 3 studies for Emgality demonstrated efficacy in patients with episodic and chronic migraine who had previously failed preventive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback